Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytosorbents (CTSO) Total Non-Current Liabilities (2016 - 2017)

Cytosorbents (CTSO) has disclosed Total Non-Current Liabilities for 4 consecutive years, with $13.1 million as the latest value for Q2 2017.

  • For the quarter ending Q2 2017, Total Non-Current Liabilities rose 87.33% year-over-year to $13.1 million, compared with a TTM value of $13.1 million through Jun 2017, up 87.33%, and an annual FY2016 reading of $6.5 million, up 364.95% over the prior year.
  • Total Non-Current Liabilities was $13.1 million for Q2 2017 at Cytosorbents, up from $8.2 million in the prior quarter.
  • Across five years, Total Non-Current Liabilities topped out at $13.1 million in Q2 2017 and bottomed at $1.4 million in Q4 2015.
  • Average Total Non-Current Liabilities over 3 years is $6.4 million, with a median of $7.0 million recorded in 2016.
  • Peak annual rise in Total Non-Current Liabilities hit 402.59% in 2017, while the deepest fall reached 87.33% in 2017.
  • Year by year, Total Non-Current Liabilities stood at $1.4 million in 2015, then skyrocketed by 364.95% to $6.5 million in 2016, then surged by 100.53% to $13.1 million in 2017.
  • Business Quant data shows Total Non-Current Liabilities for CTSO at $13.1 million in Q2 2017, $8.2 million in Q1 2017, and $6.5 million in Q4 2016.